[nanoPost] New treatments for cancer based on nano and bio

Company France

The currently develops drugs which are precisely targeting abnormal cells and destroying them through the controlled generation of physical or chemical reactions triggered by external activation. The drugs are composed of two parts:

- an inorganic core which, through activation(for example the application of an external field such as MRI) will cause the destruction of the targeted cells and

- a targeting molecule which will guide the Nanobiodrug to the target.

The company's products are nanoparticles with a controlled diameter smaller than 100 nanometers (or 1000 Angstroms). The core of the nanoparticle is a drug in an inactive form which can subsequently be activated to generate the therapeutic effect.

The surface of the drug contains a specific recognition Bioagent enabling molecular targeting. This targeting directs the drug towards the pathological cells or tissues. After the drug accumulates in the target tissues, an external physical activation is applied that generates a local and physical therapeutic effect destroying the pathological cells.

Activation is achieved by a magnetic field similar to that of an MRI machine, or by a laser (or other energy field). This mechanism offer the major advantage of total control of the therapeutic effect.

Majors technological benefits

- Specific activity, allowing the reduction of side-effects.

- Utilization of known and natural molecules for targeting preventing toxicology problems.

- Nanodesign allowing a free diffusion trough natural barriers without interfering with imune system.

- On-off and controlled therapy with in situ adjustable efficacy.

- Built-in safety profile.

Developments since 1999 have demonstrated the efficacy of these drugs using several models. Research carried out in vitro and in vivo has shown that these drugs have all the advantages required for an optimal benefit/risk ratio.

The results obtained have shown that their effect is entirely localized on the targeted cells. After their injection, there is no hepatic, renal or splenic uptake and specific accumulation in tumor site. This feature is consistent with treatments having no adverse side effects concerning action on healthy cells.

The drugs also have a totally controllable therapeutic effect: the company product drug is effective only in its active drug form. A company product drug alone does not possess a therapeutic effect before activation (On-Off therapy). Efficacy can be controlled by tuning external field application (time). This feature gives them an essential advantage since it eliminates a major therapeutic uncertainty in clinical trials.

Access the contact details for this post by subscribing to premium content membership. For more details on premium content membership see our membership and fees page >> or contact info@nanoposts.com.